developed an autologous formalin-fixed tumor vaccine (AFTV) for in vivo induction of killer lymphocytes, 5, 16 suppression of recurrence of hepatocellular carcinoma after primary resection, 12 and treatment of recurrent GBM in a pilot clinical trial. 6 Our previous prospective clinical trial for preliminary evaluation of the efficacy of AFTV concomitant with fractionated radiotherapy (FRT), but not with concomitant TMZ, in patients with newly diagnosed GBM (study identification no.: C000000002) demonstrated that this treatment resulted in a median overall survival (OS) duration of 19.8 months and an actuarial 2-year survival rate of 40%. However, at the time of disease progression, TMZ (as approved by the Japanese government on September 15, 2006 ) at a dose of 150-200 mg/m 2 daily for 5 days every 28 days (maintenance TMZ) was administered to 20 out of 22 patients. 15 Treatment with AFTV was not accompanied by severe toxicity. 12, 15 Recent preclinical studies show that vaccination with dendritic cells followed by chemotherapy can significantly increase survival in patients with malignant glioma. 13 In animal studies, TMZ shows the potential to enhance antitumor immunity. 10, 14, 19 In our pilot study, AFTV combined with TMZ was used to treat 1 patient with primary GBM and 2 patients with secondary GBM. 17 All patients demonstrated pathological improvement associated with the therapy, and the adverse effects related to AFTV plus TMZ were very minor.
These results prompted us to perform the present prospective clinical trial to look for safety and positive efficacy of AFTV in the survival of patients with newly diagnosed GBM treated with standard chemoradiotherapy (that is, primary resection followed by FRT with concomitant TMZ and periodic maintenance TMZ 23 ).
Methods

Study Design
A prospective Phase I/IIa clinical trial of AFTV and maintenance TMZ after FRT concomitant with TMZ for the management of newly diagnosed GBM was conducted by the Association of Cancer Vaccine Therapy in 3 participating hospitals: Tsukuba University Hospital (Ibaraki, Japan), Tokyo Women's Medical University Hospital (Tokyo, Japan), and Oita University Hospital (Oita, Japan). The basic objectives were focused on preliminary evaluation of the therapeutic efficacy and safety of the treatment. The primary end point was OS, and the secondary end point was progression-free survival (PFS). For reference, these outcomes were compared with those in the previous study using AFTV (C000000002). 15 The study design and treatment protocol were approved by the ethics committees of all 3 institutions and registered in the University Hospital Medical Information Network (UMIN) clinical trials registry (http://www.umin.ac.jp/ctr/), and the trial's registration number is UMIN000001426. Eligibility and exclusion criteria for patient enrollment are as follows.
The eligibility criteria were 1) age 16-75 years, 2) newly diagnosed GBM with histopathological confirmation of diagnosis of the disease with typical neurological symptoms, 3) maximum possible resection of the tumor (radiologically confirmed maximal removal leaving residual neoplasm within the vital, functionally essential brain areas), 4) availability of at least 1.5 g of neoplastic tissue for AFTV preparation, 5) possibility of in-house AFTV preparation and administration, 6) possibility of complete course of postoperative FRT with a cumulative dose of 60 Gy, 7) Karnofsky Performance Scale (KPS) score ≥ 60% before initiation of FRT, 8) possibility of regular followup evaluation, and 9) lymphocyte count ≥ 1000 per mm 3 before initiation of FRT.
The exclusion criteria were 1) treatment with glucocorticoids or antitumor chemotherapy, 2) intracranial hypertension before initiation of FRT, 3) suppressed hematological function according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 25 or absolute white blood cell count ≤ 2000/mm 3 , 4) decompensated function of internal organs, 5) malignant tumor other than GBM, 6) planned or existing pregnancy, 7) enrollment in another clinical trial within the 6 months preceding the present study, and 8) ineligibility as judged by the principal investigator of the participating institution.
All criteria except the lymphocyte count were the same as those in the previous clinical trial using AFTV.
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Written informed consent for participation in the study was obtained in each individual case. The 3-year study period started on November 1, 2008, and enrollment of 25 patients was planned, as in the previous study, but only 24 patients were actually enrolled in the present study.
After in-house confirmation of the histopathological diagnosis of GBM following resection of a newly diagnosed parenchymal brain tumor, the eligible patients who agreed to participate in the study were scheduled for FRT and concomitant TMZ, followed by treatment with AFTV and maintenance TMZ according to the standard protocol (Fig. 1A) .
The histopathological diagnosis was independently confirmed in the Japan Brain Tumor Reference Center (JBTRC, representative Y.N.) at Gunma University (Maebashi, Japan) according to the current WHO criteria, using paraffin-embedded tissue sections stained with hematoxylin and eosin in each enrolled case. Additional immunohistochemical analysis included evaluation of positive cells using monoclonal antibodies for MIB-1 (Dako), p53 (Dako), major histocompatibility complex (MHC) Class I (AB-46, Hokudo Co.), O6-methylguanine-DNA methyltransferase (MGMT) (clone MT3.1, MAB16200, Merck Millipore), and isocitrate dehydrogenase-1 (IDH1) R132H (D299-3, MBL).
The corresponding staining indices were calculated as the average number of positive cells in the best-stained tumor areas (up to 5) with a total number of cells not less than 1000. The MIB-1, p53, and MGMT indices were expressed as percentages. For category analysis, cases with 10% or more positive cells were rated as positive, and cases with fewer than 10% positive cells were rated as negative for both MGMT and p53. 24 The negative MGMT expression was correlated with positive MGMT promoter methylation. For IDH1R132H positivity, cases with 50% or more positive cells were rated as positive, and cases with fewer than 50% positive cells were rated as negative. MHC Class I expression was graded as 0 (absence of staining), + (up to 25% of cells stained), ++ (25%-50% of cells stained), or +++ (more than 50% of cells stained). 1, 6, 15 The baseline clinical investigations at the time of en- B: PFS curve for the 24 patients in the present study. Comparison of PFS in subgroups of patients stratified by recursive partitioning analysis (RPA) Class (Class III, n = 8; Class IV, n = 10; Class V, n = 6) (p = 0.0012, log-rank test); in IDH1R132H-positive (n = 5) and negative (n = 18) cases (p = 0.14, log-rank test); and in DTH-2 positive (n = 9) and negative (n = 14) cases (p = 0.0071, log-rank test). C: OS curve for the 24 patients in the present study. Comparison of OS in subgroups of patients stratified by RPA class (p = 0.0059, log-rank test), IDH1R132H status (p = 0.023, log-rank test), and DTH-2 response cases (p = 0.061, log-rank test). The x-axis indicates months; the y-axis, survival ratio. mOS = median OS; mPFS = median PFS. rollment in the trial included physical examination with evaluation of KPS scores, determination of the Medical Research Council (MRC) neurological functional grade, blood and urine tests, electrocardiogram, chest radiograph, and brain MRI obtained initially within 3 days after surgery and additionally just before the first FRT session. The data were managed by Tsukuba Critical Path Research and Education Integrated Leading (CREIL) Center at the University of Tsukuba and confirmed by the data and safety monitoring committee of this study.
Treatment Protocol
All enrolled patients received the standard Stupp regimen 23 with a modified TMZ maintenance cycle. In brief, FRT was started within 2-3 weeks after resection of the neoplasm and included focal irradiation of the tumor cavity or residual lesion including 2 cm of perifocal margin with 2 Gy per fraction up to a total dose of 60 Gy, with daily concurrent TMZ at 75 mg/m 2 throughout the course of radiotherapy. Four weeks after the end of FRT, the patients received 150 mg/m 2 /day of TMZ maintenance chemotherapy for 5 days, followed by 100-200 mg/ m 2 /day of TMZ for 5 days in each 28-day cycle. AFTV was prepared using autologous formalin-fixed GBM tissue according to an established standard operating procedure. 6, 15 The AFTV treatment consisted of 3 courses of vaccination performed at 1-week intervals. The first course corresponded to the 1st day of TMZ maintenance chemotherapy. AFTV injection was started during the first cycle of TMZ maintenance in 22 patients and during the second cycle of TMZ maintenance in 2 patients with severe lymphopenia. Each course consisted of 5 local intradermal injections of 0.2 ml AFTV per site in the upper arm. Two delayed-type hypersensitivity (DTH) tests were performed 48 hours before the first vaccination (DTH-1) and 2 weeks after the third vaccination (DTH-2). For these tests, fixed autologous tissue fragments (10% [v/v] suspended in 0.1 ml saline without immune adjuvant) were injected intradermally into the forearm, and the response was evaluated by measuring the diameter of the local erythema and induration.
Follow-Up
Follow-up investigations were performed 2 weeks (14 ± 2 days) after completion of FRT and every 2 months thereafter. Follow-up examinations included physical examination with evaluation of KPS score, determination of MRC neurological functional grade, a blood test, and brain MRI. Adverse effects of treatment were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
25 Axial, coronal, and sagittal views of gadolinium-enhanced T1-weighted MRI sequences (slice thickness ≤ 4 mm) and at least axial images of plain T1-and T2-weighted sequences were acquired every 2 months. The MRI data were evaluated by neuroradiologists in each hospital who were independent of the study, verified by the neuroradiological conference, including members who were blind to this study. All investigated data including evaluation results of the MRI studies were managed by the CREIL Center and confirmed by the data and safety monitoring committee. In this study, disease progression was defined as a 25% or greater increase in the volume of the gadolinium-enhanced lesion or appearance of new brain lesions. Stable disease/incomplete response was defined as a 24% increase to a 99% decrease without appearance of new brain lesions, and complete response was defined as disappearance of all of the enhanced lesion. Pseudoprogression was determined by continued follow-up MRI. If the lesion continued to enlarge, the initial progression was called true disease progression; if the lesion stabilized or shrank, the initial progression was confirmed as pseudoprogression and categorized into stable disease/incomplete response or complete response.
TMZ maintenance chemotherapy for 5 days in each 28-day cycle was only continued until the occurrence of severe adverse effects or tumor progression. At the time of tumor progression, salvage or second-line chemotherapy was administered at the investigators' discretion; most patients received additional chemotherapy with TMZ only or TMZ plus interferon beta and/or bevacizumab.
End Points and Statistical Analysis
The primary end point of the present clinical trial was OS, defined as the time interval from the date of surgery to death from any cause. Secondary end points were PFS and safety of the treatment. The following pre-specified factors were analyzed for their association with OS and PFS: age, sex, tumor size before surgery, preoperative KPS score, recursive partitioning analysis (RPA) class, extent of tumor resection, MIB-1 staining index, p53 staining index, MHC Class I expression grade, and size of DTH-2 response using data from the 24 patients enrolled in the present study for all analyses and the 22 patients enrolled in the previous study for some analyses. Univariate analysis was performed using a log-rank test after construction of Kaplan-Meier survival curves. Continuous variables were dichotomized on the basis of their median values. Factors that showed statistical significance were included in a Cox proportional hazard model for multivariate analysis. For data analysis, the Fisher exact test, Student t-test, or Mann-Whitney U-test was used as appropriate. Differences were considered statistically significant if the 2-tailed p value was < 0.05 in all statistical analyses.
Results
Characteristics of the Enrolled Patients
From November 1, 2008, to December 31, 2011, 26 patients with newly diagnosed GBM were enrolled into this prospective clinical trial (11 in Tsukuba University Hospital, 14 in Tokyo Women's Medical University Hospital, and 1 in Oita University Hospital). Two of the 26 patients were subsequently excluded. The patient in Case 3, after initially agreeing to participate in the study, refused a scheduled AFTV injection after FRT concomitant with TMZ and dropped out of our follow-up program. Another patient (Case 19) was excluded from the final analysis because the investigators noticed that a criterion regarding the KPS score did not meet the eligibility criteria after written informed consent was obtained.
Patient characteristics of the remaining 24 patients are presented in Table 1 . These 24 patients included 17 men and 7 women aged 26 to 66 years (mean 48 years). The median preoperative KPS score was 80%; the preoperative KPS score was 90% or 100% in 9 patients, 70% or 80% in 9, 60% in 4, and 50% in 2. All patients had KPS scores of at least 60% by the time of initiation of FRT. Regarding RPA classification, 4 8 cases were Class III, 10 cases Class IV, and 6 were Class V. The tumor lesions were mainly located in the frontal lobe in 10 cases, the temporal lobe in 9 cases, the parietal lobe in 3 cases, and the occipital lobe in 2 cases. In 18 cases the lesions were located in a single lobe, and in 6 they were in multiple lobes. In 14 cases, the lesions were on the right side, in 8 they were on the left, and in 2 they were bilateral. The maximum tumor diameter before surgery varied from 14 to 105 mm (mean 54 mm). In 16 cases (67%), resection of the neoplasm was considered total (resection of 98% or more of the contrast-enhancing lesion); and in 8 (33%), resection was partial: 90% in 2 patients, 90%-94% in 3, and 95%-97% in 3.
In all cases, the histopathological diagnoses independently confirmed in the JBTRC were GBM. The MIB-1 staining index varied from 8.7% to 48.0% (median 28.7%). The p53 staining index varied from 0% to 65.5% (median 3.5%). The grades of MHC Class I expression were evaluated for 22 cases and were + in 4 cases, ++ in 10 cases, and +++ in 8 cases. Positive IDH1R132H staining was seen in 5 of the 23 cases in which it was evaluated, and negative staining was seen in 18 cases. We found no evident differences between the present study and a previous vaccine study (C000000002, n = 22), 8 except for a lower positive response (≥10 mm local erythema) ratio in the DTH-2 test (39% vs 77%, p = 0.0156, Fisher direct method). Therefore, we adopted the data from the previous study as a historical control for further comparative analyses.
Patient Survival Benefit
In the present study, the overall length of follow-up varied from 7.3 to 48.7 months (median 19.6 months), and the length of follow-up in the surviving patients varied from 14.5 to 48.7 months (median 29.3 months). At the time of data analysis, 10 patients (42%) were alive and 14 (58%) had died. No patient showed a positive response to the DTH-1 test, whereas response to the DTH-2 test varied in size from 0 to 20 mm (median 5 mm, mean 7 mm).
The duration of PFS of the 24 patients varied from 3.4 months to 46.4 months (median 8.2 months) ( Table 2 and Fig. 1B) . The length of follow-up in the progressionfree patients varied from 18.9 to 48.7 months (median 29.5 months). In particular, we note that many patients had a long PFS in the present study. The percentage of patients with a PFS of 24 months or more was 33%; PFS showed a statistically significant association with patient age, KPS score, RPA class, extent of tumor removal, IDH1 positivity, and DTH-2 response in the 24 patients in the present study ( Table 2 ). The duration of PFS in patients with a DTH-2 response of 10 mm or larger was significantly longer than in patients with a smaller DTH-2 response. The median PFS values in cases with RPA Class III, IV, and V were over 29.5 months (PFS curve not reaching the 50% survival point), 8.2 months, and 4.9 months, respectively (Fig. 1B) . When analysis was performed with data from the 18 patients with preoperative KPS scores of 70% or greater, the median PFS was 16.4 months.
As shown in Table 2 and Fig. 1C , the median OS of the 24 patients in the present study was 22.2 months (95% CI 2.7-41.7 months). The actuarial 2-and 3-year survival rates were 47% and 38%, respectively. The duration of OS showed a statistically significant association with preoperative KPS score, RPA class (III/IV vs V), and extent of tumor removal with the log-rank test. The median OS values in cases with RPA Class III, IV, and V were over 29.3 (OS curve not reaching the 50% survival point), 20.3, and 12.0 months, respectively (Fig. 1C) . When analysis was performed with the 18 patients with preoperative KPS scores of 70% or greater, the median OS value did not reach the 50% survival point, and the actuarial 2-year survival rate was 60.6%. In patients with a DTH-2 response size of 10 mm or larger, the OS curve did not reach 50% survival point. The OS tended to be longer than in patients who had a DTH-2 response size smaller than 10 mm, although the difference was not statistically significant with the logrank test ( Table 2 ). The duration of PFS showed a statistically significant association with IDH1R132H positivity (Fig. 1B) , but no association with p53, MIB-1 indexes, or MHC Class I positivity. We found a statistically significant relationship between IDH1R132H positivity and the MIB-1 index (< 30%) (p = 0.045, Fisher direct method), but we found no relationship between IDH1R132H positivity and any other patient factors, including DTH-2 (p > 0.1, Fisher direct method).
When analysis was performed with all 46 patients from the 2 studies (the present study and the previous study, C000000002), the median PFS and OS were 7.5 months (95% CI 4.8-9.8 months) and 21.4 months (95% CI 14.3-28.5 months), respectively. Univariate analysis using combined patient data from the 46 patients in the 2 studies showed that the OS differed significantly between the subgroups for patient age (≥ 50 vs < 50 years, p = 0.0076), preoperative KPS score (≥ 80% vs < 80%, p = 0.0077), and RPA class (III/IV vs V, p = 0.0003). Progression-free survival was significantly different between subgroups in the study type (present study vs previous study, p = 0.038), patient age (p = 0.022), preoperative KPS score (p = 0.030), RPA class (p = 0.0084), extent of tumor removal (p = 0.0033), and DTH-2 response (p = 0.013), and tended to be different between subgroups stratified by sex (men vs women, p = 0.095). In particular, as shown in Fig. 2A , among these 7 factors, study type and DTH-2 response were independently associated with a favorable PFS outcome on multivariate analysis using the Cox proportional hazard model. Figure 2B -E shows that we observed clear differences between the PFS curve in the subgroup of patients categorized by study type and DTH-2 response, whereas we found only a tendency in OS. The DTH-2-positive subgroup showed a median OS of 26.9 months and a median PFS of 13.8 months.
Analysis of Lymphocyte Count and DTH-2 Response
In the present study, the mean lymphocyte counts just before chemoradiotherapy and just before AFTV injection were 1459 cells/mm 3 ). As shown in Fig.  3A -C, the minimum lymphocyte count was moderately correlated with the lymphocyte count just before chemoradiotherapy and was weakly correlated with the size of the DTH-2 response. The minimum lymphocyte count was the only factor associated with the size of the DTH-2 response. When OS was compared in subgroups stratified by lymphopenia grade (Grade 0-2, 3, and 4), patients with Grade 3 lymphopenia (median OS surpassed the followup period) probably had better survival than others (median OS 16.5 months), including those with Grade 0-2 (median OS 22.2 months) or Grade 4 (median OS 12.9 months) (Fig. 3D) , although the difference in DTH-2 positivity between the 2 groups was not statistically significant (p > 0.99, Fisher direct method).
Treatment Safety
An AFTV treatment with TMZ maintenance after FRT concomitant with TMZ treatment was well tolerated by all patients (Table 3) . We observed 28 events probably related to AFTV injection and 160 events mainly related to TMZ, FRT, and antiepileptic drugs. The most frequent AFTV-related adverse effect was skin irritation consisting of local erythema, induration, and swelling at the injection sites, and included 19 events corresponding to Grade 1 toxicity and 1 event corresponding to Grade 2. Other AFTV-related adverse effects were fever in 3 cases, appetite loss in 1 case, seizures in 2 cases, and headache in 2 cases, all of which corresponded to Grade 1 or 2 toxicities.
We found no evidence of any autoimmune phenomena as AFTV-related adverse effects.
Discussion
One of the basic objectives of this study was to test the safety of AFTV treatment concomitant with TMZ after FRT and TMZ treatment. Indeed, AFTV treatment with TMZ resulted in only minor adverse events categorized as CTCAE Grade 1 or Grade 2, similar to those in the previous study using EGFRvIII (epidermal growth factor receptor variant III) peptide vaccine. 18 Aggressive treatments using radiotherapy followed by adjuvant TMZ with chemotherapeutic agents previously showed the best OS (28 months). 9 However, in that study, the enrollment was stopped due to an unacceptable frequency of toxicity related to the neoadjuvant chemotherapeutic agents. Clinical use of 6 weeks of continuous TMZ often causes Grade 3 or 4 lymphopenia, 7, 11 and this was seen in the present study. Some animal studies have indicated that TMZ may enhance antitumor immunity. 10, 14, 19 In a murine model of an established intracerebral tumor, vaccination-induced immunity in the setting of myeloablative TMZ, but not non-myeloablative TMZ, leads to significantly prolonged survival. 19 These data are consistent with our interesting result that the median OS in patients with Grade 3 lymphopenia was superior to that in patients with Grade 0-2 lymphopenia. A similar result was reported in melanoma patients in whom the development of Grade 2 lymphopenia was positively correlated with the clinical outcome. The data demonstrated that specific CD8 + T-cell responses against selected tumor-associated antigens are enhanced by the administration of TMZ. 8 On the other hand, severe lymphopenia (Grade 4) re- sulted in worse OS in the patients in the present study, probably due to minimal immunoreactivity. Indeed, our studies indicated that the DTH-2-positive ratio in patients with severe lymphopenia was lower than in those with milder grades of lymphopenia. This lower immunoreactivity may be due to improper timing of AFTV injection after myeloablative TMZ in the present study. If DTH-2 positivity is established even in patients with severe lymphopenia after using myeloablative TMZ, we believe that a median OS over 24 months can be expected. These results were not inferior to those in other studies using TMZ 2, 18, 20, 23 in which patients with a preoperative KPS score of 70% (or 80%) or more were enrolled. However, to be exact, the results are comparable only to previously published data from our group, because our study differs from the previous other studies in inclusion criteria and neuroradiological assessments. In the combined 46 patients in the present study and our previous study using AFTV, the DTH-2 response and study type, but not patients' KPS score or extent of tumor removal, were independent factors associated with a favorable PFS outcome on multivariate and univariate analyses. The DTH-2-positive subgroup showed a median OS of 26.9 months and a median PFS of 13.8 months. Thus, we speculate that AFTV therapy combined with chemoradiotherapy led to the favorable outcomes.
As a limitation of the present study, some characteristics of our patient group, including age, were not typical for GBM patients in general (patient age in this study was slightly younger than those in other studies). 2, 18, 20 Indeed, about 20% of GBM patients in each hospital were enrolled in this study, mainly owing to patients' participation in other clinical studies and not meeting the inclusion criteria (for example, some patients had smaller tumors or could not be treated with maximal resection because of tumor depth). These selection biases might affect outcome. In the present study, we found that 5 of the patients had IDH1R132H-positive GBM, which is usually associated with a better clinical outcome. However, even in patients with IDH1R132H-negative GBM, the median OS was 20.3 months. IDH1R132H and DTH-2 were not significantly associated with each other. This study does not prove efficacy for the combination of FRT, TMZ, and AFTV, which was just compared with a previous similar study consisting of FRT and AFTV injection with different timing. To address this, we are now beginning a new prospective randomized study of FRT, TMZ, and AFTV versus FRT, TMZ, and placebo. In addition, the present study may contain a bias due to a high total resection rate (67%), which was higher than in previous studies from other institutions. Stummer et al. reported that the median OS surpassed the follow-up period (24 months) in patients with no residual tumor and was 16.9 months in patients with residual tumor diameters of no more than 1.5 cm. 22 However, even in the partial resection subgroup or the patients with lower KPS scores (< 80%) in our study, the median OS was over 14 months.
Conclusions
The regimen in this clinical trial consisting of FRT concomitant with TMZ followed by AFTV and TMZ maintenance in patients with newly diagnosed GBM was well tolerated and resulted in a median OS of 22.2 months and a median PFS of 8.2 months. A further randomized trial using AFTV will be promising.
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